LYKALABS vs ONESOURCE: Stock Comparison
ONESOURCE SPECL PHARMA L is the larger company by market capitalisation. ONESOURCE SPECL PHARMA L shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LYKALABS leads 2; ONESOURCE leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LYKALABS | ONESOURCE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LYKALABS | ONESOURCE |
|---|---|---|
| Live Price | ₹74.83 | ₹1,588.9 |
| Day Change | 1.19% | 1.23% |
| Volume | 88,556 | 2,353 |
| 52-Week High | ₹98.25 | ₹1,925 |
| 52-Week Low | ₹44.1 | ₹1,057 |
| Distance from 52W High | -23.84% | -17.46% |
Valuation
| Metric | LYKALABS | ONESOURCE |
|---|---|---|
| Market Cap | ₹279 Cr | ₹17,971 Cr |
| P/E Ratio | 0x | 0x |
| P/B Ratio | 2.67x | 3.08x |
| EPS | ₹0.57 | ₹2.18 |
| Book Value | ₹25.12 | ₹508.64 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | LYKALABS | ONESOURCE |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0.5% |
| EPS Growth (TTM YoY) | 0% | -95.3% |
| Qtr Sales Growth | 0% | 4.86% |
| Qtr Profit Growth | 0% | 443.77% |
Profitability & Leverage
| Metric | LYKALABS | ONESOURCE |
|---|---|---|
| ROE | -37.11% | -1.27% |
| ROCE | -22.29% | 0.43% |
| Net Margin | -7.81% | -5.19% |
| Operating Margin | -24.74% | 2.13% |
| Debt to Equity | 0.56x | 0.22x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | LYKALABS | ONESOURCE |
|---|---|---|
| Promoter Holding | 58.45% | 30.47%▼ 0.01 pp |
| FII Holding | 0.15%▼ 0.02 pp | 19.46%▲ 0.27 pp |
| DII Holding | 0.66% | 24.21%▲ 0.83 pp |
| Public Holding | 40.73%▲ 0.01 pp | 25.86%▼ 1.08 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LYKALABS and ONESOURCE SPECL PHARMA L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.